Bristol Myers pauses Zola-Cel review to assess clinical data
Bristol Myers spokesperson said the company implemented a voluntary pause to review clinical data across its Zola-Cel program.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.